Clarity Pharmaceuticals Secures Scalable Cu-64 Supply via Theragenics Deal

The radiopharmaceutical sector is currently undergoing a massive transformation, shifting from a niche oncology field to a central pillar of precision medicine. At the heart of this shift is the "theranostic" approach—pairing diagnostic imaging with targeted therapy. Clarity Pharmaceuticals has taken a significant step in securing its position in this market by signing a large-scale Manufacturing Supply Agreement with Theragenics for the production of copper-64 (Cu-64). This deal is not merely a procurement contract; it is a strategic move to solve the supply chain and logistics problems that have historically limited the adoption of radiopharmaceuticals.

Historically, the diagnostic radiopharmaceutical market has been dominated by Fluorine-18 (F-18), which has a half-life of only 110 minutes. This short window necessitates that manufacturing facilities be located within a few hours' drive of the hospital where the patient is treated. This "just-in-time" model is expensive, prone to disruption, and severely limits access to rural or remote areas. Copper-64, however, offers a compelling alternative. With a half-life of 12.7 hours, Cu-64 can be produced at a central facility and shipped across the country, or even internationally, without losing its diagnostic efficacy. By partnering with Theragenics, a company with deep expertise in cyclotron-produced isotopes, Clarity is effectively building a centralized supply chain that can scale to meet global demand.

“

Clarity Pharmaceuticals has taken a significant step in securing its position in this market by signing a large-scale Manufacturing Supply Agreement with Theragenics for the production of copper-64 (Cu-64).

Theragenics brings to the table a robust infrastructure that is critical for the high-purity production of Cu-64. Unlike some other isotopes that require nuclear reactors, Cu-64 is produced using cyclotrons—particle accelerators that can be housed in more flexible, less regulated environments than reactors. This agreement ensures that as Clarity moves its pipeline toward Phase III trials and eventual commercialization, it will not face the supply shortages that have recently hampered other major players in the radiopharmaceutical space. The reliability of cyclotron production is a key differentiator in a market where reactor-based isotopes like Lutetium-177 have faced significant supply volatility.

The implications for Clarity’s Targeted Copper Theranostics (TCT) platform are profound. The TCT platform relies on the chemical "twin" nature of copper isotopes: Cu-64 for imaging and Cu-67 for therapy. Because they are the same element, the biodistribution of the diagnostic agent perfectly matches that of the therapeutic agent. This "perfect pairing" allows for more precise dosing and better patient outcomes. Securing the Cu-64 supply is the first half of this equation, providing the diagnostic foundation upon which the therapeutic success of Cu-67 will be built.